Is colistin safe for long-term use?

Colistin is not recommended for prolonged indefinite therapy due to cumulative nephrotoxicity and neurotoxicity risks. It's typically used for acute serious infections for days to weeks, with close monitoring of kidney function and neurological status. Inhaled colistin in cystic fibrosis is an exception, where chronic low-dose inhalation is standard practice with minimal systemic toxicity. Always balance infection severity against toxicity risk with your clinical team.

Can bacteria become resistant to colistin?

Yes. While colistin resistance was rare historically, plasmid-mediated mcr genes have enabled bacteria to modify their membrane composition and evade colistin killing. Resistance is still uncommon globally but has been documented in Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae. This makes antibiotic stewardship—using colistin only when truly necessary—essential to preserve its effectiveness.

How is colistin dosed?

Dosing varies by formulation, route, and indication. Intravenous colistin requires careful dose adjustment based on kidney function; standard dosing ranges from 2.5–5 mg/kg/day split across multiple infusions. Inhaled colistin for cystic fibrosis is typically 75 mg twice daily via nebulizer. Dosing protocols must be individualized—we cannot provide specific guidance; discuss dosing with your prescribing physician.

What's the difference between colistin and other polymyxins?

Colistin (polymyxin E) is one member of the polymyxin family; polymyxin B is another. Both have similar mechanisms and toxicity profiles. Polymyxin B is used primarily in topical preparations and ophthalmic formulations. Colistin has more extensive intravenous and inhaled clinical use and more robust clinical trial data, making it the preferred systemic polymyxin in many regions.

Why was colistin abandoned and then brought back?

Colistin was developed in the 1950s but fell from favor in the 1970s–1990s as newer, less toxic antibiotics became available (fluoroquinolones, beta-lactams). However, as bacteria developed resistance to these newer drugs, colistin—one of the few remaining weapons against multidrug-resistant pathogens—experienced a clinical revival starting in the 2000s. It's a clear example of how antimicrobial resistance paradoxically resurrects old, previously undesirable drugs.

Colistin: Antibiotic Peptide for Resistant Infections

Colistin is an FDA-approved polymyxin antibiotic peptide developed in the 1950s and now recognized as a critical weapon against multidrug-resistant gram-negative bacteria. Unlike many modern drugs, colistin gained prominence only recently—after decades of limited use—because bacteria have become resistant to nearly everything else. It's approved by the FDA, EMA, and Health Canada, and has been evaluated in over 119 clinical trials. Colistin works by disrupting bacterial cell membranes, making it lethal to organisms like Pseudomonas aeruginosa and Acinetobacter baumannii. However, it carries real toxicity risks, particularly to the kidneys and nerves. For patients with serious infections from resistant pathogens, colistin often represents a last-resort option when conventional antibiotics fail.

What Is Colistin? The Peptide Antibiotic You Never Knew You Needed

Colistin (also called polymyxin E) is a cyclic peptide antibiotic originally isolated from the bacterium Bacillus polymyxa in the 1950s. It belongs to the polymyxin family of antibiotics—a tiny class of potent antimicrobial peptides that fell out of favor for decades due to toxicity concerns, only to become invaluable as bacterial resistance spiraled out of control.

The compound is composed of 10 amino acids arranged in a cyclic structure with a long fatty acid tail (diaminobutyric acid chain). This unusual architecture is key to its mechanism: the fatty tail anchors the peptide into bacterial membranes, while the cyclic portion perforates the cell wall. It's a blunt-force approach to killing bacteria—effective, but with consequences for human tissue too.

Bacitracin, another peptide antibiotic from a similar era, offers a contrasting example: it's too toxic for systemic use and remains limited to topical applications. Colistin, by comparison, can be given intravenously or via inhalation because its toxicity profile, while concerning, is manageable under clinical supervision.

How Colistin Works: Membrane Disruption at the Molecular Level

Colistin's mechanism is elegantly simple and devastatingly effective. The peptide's cationic (positively charged) nature allows it to bind to lipopolysaccharides (LPS) on the outer membrane of gram-negative bacteria. Once bound, the lipophilic (fat-soluble) portion of the molecule inserts into the bacterial lipid bilayer, causing membrane depolarization and leakage of cellular contents. The bacteria literally lose the ability to maintain osmotic balance and die.

This mechanism explains both colistin's broad activity against gram-negative pathogens and its toxicity profile. Human cells also have lipid membranes, and colistin can disrupt them too—particularly in the kidneys (nephrotoxicity) and peripheral nerves (neurotoxicity). The difference is one of degree: bacterial membranes are more susceptible because of their chemical composition, but mammalian tissue damage is a real risk, especially at higher doses or with prolonged exposure.

Colistin is bactericidal, meaning it kills bacteria outright rather than merely inhibiting growth. This is generally preferable for serious infections, though it also means dosing must be precise: too little, and resistance can develop; too much, and organ damage may follow.

Regulatory Approval and Global Status

Colistin holds FDA approval in the United States, EMA authorization in Europe, and Health Canada approval in Canada. In the U.S., colistin sulfate (inhalation) was approved by the FDA in 1970, and colistin methanesulfonate (intravenous) gained formal approval through accelerated pathways as resistance concerns escalated in the 2000s.

Accelerated Approval mechanisms have played a role in bringing colistin and similar antimicrobials to market faster when clinical need is acute. The compound's regulatory history reflects a broader shift in how agencies evaluate antibiotics—recognizing that traditional long-term efficacy trials are sometimes impractical when patients face life-threatening resistant infections and no alternatives exist.

The EMA similarly authorized colistin products, including intravenous and inhaled formulations, for severe infections caused by multidrug-resistant aerobic gram-negative organisms. Health Canada's approval aligns with these authorizations, making colistin available across North America and Europe—a critical availability given the global nature of antimicrobial resistance.

Clinical Evidence: 119 Trials and Counting

Colistin has been the subject of over 119 clinical trials, ranging from small observational studies to comparative effectiveness trials. This trial volume is substantial for an antibiotic, reflecting both its historical use and recent resurgence in the face of resistance.

A landmark systematic review published in 2019 examined pooled data from multiple studies and found that intravenous colistin was effective in treating serious infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, with clinical success rates ranging from 40% to 70% depending on infection type and patient factors. These numbers, while not spectacular compared to first-line antibiotics, are remarkable given the context: these are infections that have already defeated multiple other drugs.

A 2020 trial comparing colistin monotherapy to colistin combination therapy suggested that combining colistin with other agents (such as rifampicin or carbapenems) may improve outcomes for serious infections like ventilator-associated pneumonia, though the evidence remains mixed and patient-specific factors dominate decision-making.

Inhaled colistin has also been extensively studied in cystic fibrosis patients chronically colonized with Pseudomonas aeruginosa. A 2016 Cochrane review found that inhaled colistin reduces bacterial density in sputum and may improve lung function, making it a standard option for CF patients with resistant Pseudomonas infections.

Spectrum of Activity: What Colistin Kills

Colistin's primary strength is activity against multidrug-resistant gram-negative bacteria. The main clinical targets are:

Pseudomonas aeruginosa: A common opportunistic pathogen in hospitalized patients, especially those on ventilators. Colistin remains highly active even against extensively resistant strains.
Acinetobacter baumannii: An increasingly problematic nosocomial (hospital-acquired) pathogen that often develops resistance to carbapenem antibiotics. Colistin is frequently one of the last effective options.
Enterobacteriaceae with extended-spectrum beta-lactamase (ESBL) production: Organisms like Klebsiella pneumoniae and Escherichia coli that produce enzymes destroying beta-lactam antibiotics.

Colistin has limited or no activity against gram-positive bacteria, anaerobes, or many atypical organisms. This narrow spectrum actually makes it safer for microbiome preservation—when used, it targets only the resistant gram-negative pathogens causing the infection rather than indiscriminately killing normal flora.

Safety Profile: Toxicity You Need to Know About

Colistin's resurgence in clinical practice represents a conscious trade-off: accepting known toxicity risks because the alternative—untreatable infection—is worse. Understanding these risks is essential for clinicians and patients alike.

Nephrotoxicity

Kidney damage is the most common serious adverse effect. A 2017 meta-analysis of nephrotoxicity found that acute kidney injury occurred in 25% to 60% of patients receiving intravenous colistin, depending on study population and dosing strategies. Most cases are reversible upon drug discontinuation, but in patients with pre-existing renal impairment, damage can be severe and prolonged. Dose adjustment based on renal function is critical.

Neurotoxicity

Peripheral neuropathy, paresthesia (abnormal sensations), and rarely, neuromuscular blockade have been reported. These effects are dose-related and typically emerge with prolonged therapy. They're usually reversible but can be distressing for patients and warrant close monitoring.

Drug Interactions

Colistin's narrow therapeutic index means careful consideration of concomitant medications. Concurrent use of other nephrotoxic agents (vancomycin, aminoglycosides, NSAIDs, contrast agents) significantly increases kidney injury risk. Similarly, neuromuscular blockers and medications affecting neuromuscular transmission warrant caution.

Inhaled Colistin

When given by inhalation (as in cystic fibrosis), colistin concentrates in the lungs and produces minimal systemic toxicity. Bronchospasm and throat irritation are the primary local side effects, easily managed with bronchodilators.

Resistance: The Enemy Colistin Still Faces

While colistin remains active against many multidrug-resistant pathogens, resistance has begun to emerge. The most concerning development is the spread of plasmid-mediated mcr genes, which can be transferred between bacteria and confer colistin resistance by modifying bacterial lipopolysaccharides. This mechanism was first identified in China in 2015 and has since been detected globally.

This evolution underscores a critical reality: no antibiotic is forever. Colistin's window as a reliable last-resort option is finite unless antibiotic stewardship—using these precious drugs judiciously and only when truly needed—becomes standard practice.

Colistin in Clinical Practice: When It's Used

Colistin is not a first-line antibiotic for any infection. Instead, it's reserved for situations where:

Confirmed multidrug resistance in a gram-negative pathogen that has failed conventional therapy.
Serious infections (bacteremia, pneumonia, urinary tract infections in high-risk patients) where the infection poses immediate danger.
No suitable alternatives exist—all other targeted antibiotics have been ruled out due to resistance or contraindication.

Common clinical scenarios include ventilator-associated pneumonia (VAP) with resistant Pseudomonas or Acinetobacter, complicated urinary tract infections in critically ill patients, and bloodstream infections in immunocompromised hosts.

In cystic fibrosis, inhaled colistin is used more routinely—not as true monotherapy for acute infection, but as a maintenance inhalation therapy to suppress chronic Pseudomonas colonization and preserve lung function.

The Bigger Picture: Peptide Antibiotics and the Resistance Crisis

Colistin's story mirrors a larger narrative in antimicrobial medicine: old drugs are being recycled and repurposed because the pipeline for genuinely new antibiotics has dried up. ACE-031 and other peptide-based therapeutics in development may offer future options, but they're still years away from clinical availability for most indications.

Colistin represents what peptide science can accomplish—a small, cyclic, amino acid-based molecule with exquisite specificity for bacterial targets. Yet it also illustrates the limitations: toxicity, emerging resistance, and the difficulty in developing new drugs faster than bacteria can evolve.

The future of colistin likely involves combination therapy, optimization of dosing regimens, and careful stewardship to extend its clinical utility. Ongoing research into drug interactions, resistance mechanisms, and synergistic combinations continues to refine how clinicians deploy this critical resource.

Current Research Directions

Active investigations into colistin include:

Combinatorial approaches: Pairing colistin with novel beta-lactamase inhibitors or other agents to enhance activity and reduce dosing requirements.
Inhaled formulations: Developing optimized aerosolized formulations for respiratory infections with better lung penetration and lower systemic exposure.
Resistance surveillance: Global monitoring programs tracking the emergence and spread of colistin-resistant organisms to guide prescribing and infection control strategies.
Pharmacokinetic optimization: Refining dosing strategies to maximize bacterial killing while minimizing nephrotoxicity and neurotoxicity.

These efforts reflect the reality that colistin is here to stay—not as a permanent solution to resistance, but as a critical temporary bridge until better alternatives emerge.

Colistin: The Last-Resort Peptide Antibiotic for Superbugs